These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18495744)

  • 1. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?
    Swinkels DW; Wetzels JF
    Nephrol Dial Transplant; 2008 Aug; 23(8):2450-3. PubMed ID: 18495744
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients.
    van der Putten K; Jie KE; van den Broek D; Kraaijenhagen RJ; Laarakkers C; Swinkels DW; Braam B; Gaillard CA
    Eur J Heart Fail; 2010 Sep; 12(9):943-50. PubMed ID: 20601671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin for clinicians.
    Young B; Zaritsky J
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
    Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
    [No Abstract]   [Full Text] [Related]  

  • 5. [Iron, hepcidin and chronic kidney disease].
    Fievet P; Brazier F
    Nephrol Ther; 2011 Apr; 7(2):86-91. PubMed ID: 21186144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome.
    Kato A
    Future Cardiol; 2010 Nov; 6(6):769-71. PubMed ID: 21142632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in anemia management in chronic kidney disease.
    Amerling R; Besarab A; Roy C
    Nephrol News Issues; 2008 Mar; 22(3):suppl 1-8. PubMed ID: 18372676
    [No Abstract]   [Full Text] [Related]  

  • 9. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?
    Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Mysliwiec M
    Am J Nephrol; 2005; 25(6):586-90. PubMed ID: 16254410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepcidin in anemia and inflammation in chronic kidney disease.
    Malyszko J; Mysliwiec M
    Kidney Blood Press Res; 2007; 30(1):15-30. PubMed ID: 17215586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: treatment of anaemia with iron.
    Vaage-Nilsen O
    Nephrol Dial Transplant; 2005 Jul; 20(7):1512-3; author reply 1513-4. PubMed ID: 15967789
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response.
    Katodritou E; Ganz T; Terpos E; Verrou E; Olbina G; Gastari V; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Westerman M; Zervas K
    Am J Hematol; 2009 Aug; 84(8):524-6. PubMed ID: 19536845
    [No Abstract]   [Full Text] [Related]  

  • 13. Posttransplantation anemia: relationship with inflammatory markers, oxidation, and prohepcidin levels.
    Sancho A; Pastor MC; Cañas L; Morales Indiano C; Ardèvol M; Aguerrevere S; Juega J; Romero R; Lauzurica R
    Transplant Proc; 2011; 43(6):2196-8. PubMed ID: 21839232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemoglobin variability in dialysis patients.
    Brimble KS; Clase CM
    J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931
    [No Abstract]   [Full Text] [Related]  

  • 15. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepcidin is linked to anemia and inflammation in peritoneal dialysis patients.
    Malyszko J; Malyszko JS; Pawlak K; Drozdowska-Rams L; Brzosko S; Mysliwiec M
    Perit Dial Int; 2008; 28(4):418-21. PubMed ID: 18556388
    [No Abstract]   [Full Text] [Related]  

  • 17. [The iron hormone hepcidin: A future diagnostic marker and therapeutic target in the treatment of anemia and hemochromatosis?].
    Moestrup SK; Møller HJ
    Ugeskr Laeger; 2005 Oct; 167(41):3894-5. PubMed ID: 16221434
    [No Abstract]   [Full Text] [Related]  

  • 18. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 19. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 20. Is hepcidin the star player in iron metabolism in chronic kidney disease?
    Hamada Y; Fukagawa M
    Kidney Int; 2009 May; 75(9):873-4. PubMed ID: 19367309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.